Richard A. Bernstein, MD, PhD; Hooman Kamel, MD; Christopher B. Granger, MD; et al.
open access
has audio
JAMA Neurol. 2023;80(12):1277-1283. doi:10.1001/jamaneurol.2023.3931
This study compares the rates of atrial fibrillation detection through 3 years of follow-up between an insertable cardiac monitor vs site-specific usual care, in patients with prior ischemic stroke attributed to large-artery disease or small-vessel disease.
-
Podcast:
Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease
Michael E. Belloy, PhD; Shea J. Andrews, PhD; Yann Le Guen, PhD; et al.
open access
JAMA Neurol. 2023;80(12):1284-1294. doi:10.1001/jamaneurol.2023.3599
This genetic association study assesses associations between apolipoprotein E and Alzheimer disease risk across age, sex, race and ethnicity, and global population ancestry.
Anna Steward, MSc; Davina Biel, PhD; Anna Dewenter, PhD; et al.
free access
JAMA Neurol. 2023;80(12):1295-1306. doi:10.1001/jamaneurol.2023.4038
This cohort study evaluates amyloid-related tau spreading in apolipoprotein E ε4 carriers and amyloid positron emission tomography thresholds at which tau spreading may accelerate.
Daniel Lee, MD; Mary Slomkowski, PharmD; Nanco Hefting, MSc; et al.
open access
JAMA Neurol. 2023;80(12):1307-1316. doi:10.1001/jamaneurol.2023.3810
This randomized clinical trial examines data for patients with Alzheimer dementia to determine whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation.
Ahmed Abdelhak, MD; Pascal Benkert, PhD; Sabine Schaedelin, MSc; et al.
free access
has audio
JAMA Neurol. 2023;80(12):1317-1325. doi:10.1001/jamaneurol.2023.3997
This cohort study investigates the timing of neuroaxonal pathology in individuals with multiple sclerosis who experience disability worsening.
-
Podcast:
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
Jayandra J. Himali, PhD; Andree-Ann Baril, PhD; Marina G. Cavuoto, PhD; et al.
free access
JAMA Neurol. 2023;80(12):1326-1333. doi:10.1001/jamaneurol.2023.3889
This cohort study examines data from a sample of participants in the Framingham Heart Study who completed 2 overnight polysomnography studies to assess whether reductions in slow-wave sleep are associated with the risk of incident dementia.
A. Gordon Smith, MD; J. Robinson Singleton, MD; Adrienne Aperghis, BS; et al.
free access
JAMA Neurol. 2023;80(12):1334-1343. doi:10.1001/jamaneurol.2023.3711
This randomized clinical trial investigates if topiramate slows decline in intraepidermal nerve fiber density and/or improves neuropathy-specific quality of life in individuals with cryptogenic sensory peripheral neuropathy and concurrent metabolic syndrome.
Amanda L. Edwards, PhD; Jessica A. Collins, PhD; Candice Junge, PhD; et al.
free access
JAMA Neurol. 2023;80(12):1344-1352. doi:10.1001/jamaneurol.2023.3861
This randomized clinical trial examines data from patients with mild Alzheimer disease receiving BIIB080 to assess changes in tau biomarkers associated with cognitive decline, including cerebrospinal fluid total tau and phosphorylated tau 181 and tau positron emission tomography.
Zahra Shirzadi, PhD; Stephanie A. Schultz, PhD; Wai-Ying W. Yau, MD; et al.
free access
JAMA Neurol. 2023;80(12):1353-1363. doi:10.1001/jamaneurol.2023.3618
This cohort study investigates whether white matter hyperintensity in individuals with Alzheimer disease is more likely to be associated with neurodegeneration and parenchymal and vessel amyloidosis than with systemic vascular risk.